Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Corvus Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +11 vs. Q2 2025
- Shares held
- 42.4M
- +660.7K (+1.6%) vs. Q2 2025
- Total value
- $312.7M
- +$145.5M (+87.1%) vs. Q2 2025
- New holders
- 23
- 35 more added
- Sold out
- 12
- 17 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 173 | $1.06B |
| Q1 2026 | 164 | $1.02B |
| Q4 2025 | 124 | $359.4M |
| Q3 2025 | 103 | $312.7M |
| Q2 2025 | 92 | $167.1M |
| Q1 2025 | 88 | $115.4M |
| Q4 2024 | 86 | $202.0M |
| Q3 2024 | 62 | $158.5M |
| Q2 2024 | 47 | $50.2M |
| Q1 2024 | 47 | $31.9M |
| Q4 2023 | 48 | $33.8M |
| Q3 2023 | 52 | $28.0M |
| Q2 2023 | 52 | $44.6M |
| Q1 2023 | 37 | $18.9M |
| Q4 2022 | 42 | $18.2M |
| Q3 2022 | 48 | $18.1M |
| Q2 2022 | 47 | $25.4M |
| Q1 2022 | 57 | $44.9M |
| Q4 2021 | 62 | $66.7M |
| Q3 2021 | 61 | $136.4M |
| Q2 2021 | 50 | $63.2M |
| Q1 2021 | 49 | $62.8M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Corvus Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,710,442 | $34.7M | 0.00% | +472,032+11.1% | Added |
| Point72 Asset Management, L.P. | 6,454,274 | $47.6M | 0.10% | −588,099−8.4% | Reduced |
| OrbiMed Advisors LLC | 7,165,006 | $52.8M | 1.27% | 00.0% | Unchanged |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −201,651−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −165,188−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −138,462−100.0% | Sold out |
| BML Capital Management, LLC | 0 | $0 | 0.00% | −118,766−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −67,816−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −43,969−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −17,500−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −14,774−100.0% | Sold out |
| Sender Co & Partners, Inc. | 0 | $0 | 0.00% | −12,995−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −2,032−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −2,005−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −365−100.0% | Sold out |